Investment Rating - The report maintains a "Strong Buy" rating for ZTO Express (02057.HK) [5] Core Insights - ZTO Express achieved a total business volume of 38.52 billion packages in 2025, representing a year-on-year growth of 13.3%. In Q4 alone, the business volume reached 10.56 billion packages, up 9.2% year-on-year [1] - The adjusted net profit for the entire year was 9.51 billion, a decline of 6.3% year-on-year, while Q4 adjusted net profit was 2.69 billion, down 1.4% year-on-year [1] - The company’s market share increased from 18.8% in the same period last year to 19.6%, marking the first quarter of year-on-year market share growth since Q1 2023 [1] - The company expects a package volume of 42.37 to 43.52 billion for 2026, indicating a year-on-year growth of approximately 10%-13% [2] - The average revenue per package in Q4 was 1.35 yuan, an increase of 0.04 yuan year-on-year and 0.14 yuan quarter-on-quarter, driven by a reduction in price competition and growth in the parcel business [2] Financial Performance - In Q4, the core cost per package decreased by 0.04 yuan year-on-year, with transportation costs dropping from 0.40 yuan to 0.37 yuan and sorting costs from 0.27 yuan to 0.26 yuan [3] - The company has implemented a dividend payout policy of at least 40% of the previous year's adjusted net profit, increasing to 50% starting in 2026. Additionally, a share buyback plan of 1.5 billion USD over two years has been approved [3] - The projected net profits for 2026-2028 are 10.42 billion, 11.69 billion, and 13.08 billion respectively, with corresponding P/E ratios of 12.7X, 11.3X, and 10.1X [4]

Investment Rating - The report maintains a "Buy" rating for the company with a target price raised to HKD 37.52, reflecting a potential upside of 23.5% based on a 24.0x FY26 P/E ratio [4][6]. Core Insights - The company is expected to achieve a significant increase in FY25 shareholder net profit, projected to rise by 50.0% to RMB 1.058 billion, surpassing previous forecasts [1]. - The growth is driven by a 22.8% increase in revenue from digital energy services, reaching RMB 3.56 billion, and effective cost management leading to a 3.4 percentage point increase in operating profit margin [1]. - The digital energy services segment, which includes data center clients, has seen new order amounts increase by 11.7% to RMB 4.8 billion, with orders from data center clients specifically growing by 99.5% to RMB 1.56 billion [2]. - The company's overseas business is expanding rapidly, with revenue from international clients increasing by 25.0% to RMB 3.0 billion, significantly outpacing the overall revenue growth [3]. Financial Summary - For FY25, the company reported total revenue of RMB 10.074 billion, reflecting a growth rate of 15.6% [5]. - The shareholder net profit for FY25 is projected at RMB 1.058 billion, with a growth rate of 50.0% compared to the previous year [5]. - The earnings per share (EPS) for FY25 is expected to be RMB 1.07, with a projected P/E ratio of 25.0x [5]. - The company plans to increase its dividend per share to HKD 0.48 for FY25, representing a dividend yield of 1.6% [5].

Investment Rating - The report maintains a neutral rating for the company, 恒瑞医药 (1276 HK), with a target price of HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [2][3][11]. Core Insights - The company's revenue is expected to grow rapidly in 2025, driven by the continued ramp-up of innovative drug sales and normalized contributions from licensing income. The report highlights that innovative drugs are projected to contribute 58% of total revenue by 2025, with a 26% year-on-year growth in innovative drug sales [2][7]. - Key focus areas for 2026 include the rollout of new products included in the medical insurance list, data readouts from Phase III trials in ADC and weight loss sectors, and the potential for more business development opportunities from a robust early-stage pipeline [2][7]. - The report notes that the current valuation of the company is reasonable, with target prices corresponding to potential upsides of 5% in Hong Kong and 14% in A-shares [2]. Financial Forecasts - The updated financial forecasts for 2026 show expected revenue of RMB 35,377 million, a slight decrease of 0.6% from previous estimates. The gross profit is projected at RMB 30,707 million, with a gross margin of 86.8% [6][14]. - The net profit attributable to shareholders is forecasted to be RMB 8,887 million, reflecting a 1.7% increase from prior estimates, with a net profit margin of 25.1% [6][14]. - The company anticipates a significant increase in innovative drug sales, with a target of over 30% year-on-year growth in 2026, supported by the inclusion of 10 new drugs and 5 new indications in the national medical insurance [7][14].

Investment Rating - The report initiates coverage with an "Outperform" rating for the company [3][5]. Core Insights - The company holds the world's largest single open-pit Bakuta tungsten mine, with significant production increases expected following the completion of its Phase II construction [1][14]. - The company has turned around its financial performance, achieving a net profit of HKD 314 million in 2025, compared to a loss of HKD 177 million in 2024, with total sales revenue reaching HKD 1.063 billion [1][15]. - The entire revenue is derived from the production of white tungsten concentrate, with production starting in April 2025 and expected to ramp up significantly in the coming years [1][14]. Financial Projections - Revenue projections for 2026, 2027, and 2028 are estimated at HKD 5.31 billion, HKD 8.65 billion, and HKD 12.78 billion, respectively, reflecting year-on-year growth rates of 399%, 63%, and 48% [3][34]. - The company's net profit is projected to reach HKD 3.38 billion, HKD 5.78 billion, and HKD 8.74 billion for the same years, with growth rates of 1008%, 71%, and 51% [3][34]. - Earnings per share (EPS) are expected to be HKD 7.42, HKD 12.68, and HKD 19.17 for 2026, 2027, and 2028, respectively, with corresponding price-to-earnings (PE) ratios of 13.4x, 7.8x, and 5.2x [3][34]. Industry Overview - The domestic tungsten production is experiencing a contraction trend, which supports high tungsten prices. The Ministry of Natural Resources has imposed quota constraints on tungsten mining, with a significant reduction in mining quotas expected by 2025 [2][23]. - The report highlights that the supply of tungsten is limited both domestically and globally, with China's tungsten mining quota expected to decrease by 6.1% in 2025 [2][23]. - The Bakuta tungsten mine is positioned as a key project under the China-Kazakhstan cooperation framework, with substantial resource reserves and production capacity [14][16].

Investment Rating - The report maintains a Neutral rating for the company [3][7]. Core Views - The company is expected to achieve a revenue growth of 13% in 2025, driven primarily by the continued ramp-up of innovative drug sales and normalized contributions from licensing income [2][7]. - The target price is set at HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [1][7]. Financial Performance Summary - Revenue projections for 2026 are estimated at RMB 35,377 million, a slight decrease of 0.6% from previous forecasts [6]. - Gross profit is expected to be RMB 30,707 million, with a gross margin of 86.8% [6][14]. - Net profit attributable to shareholders is projected at RMB 8,887 million, reflecting a net margin of 25.1% [6][14]. - The company has a strong pipeline with 24 first-class new drugs and 5 second-class new drugs approved for sale in mainland China, with expectations for 53 new products/indications to be approved from 2026 to 2028 [7]. Growth Drivers - Innovative drugs are projected to contribute 58% of total revenue by 2025, with significant growth expected from new products such as 瑞维鲁胺, 达尔西利, and 恒格列净 [2][7]. - The company anticipates a 30% year-on-year growth in innovative drug sales in 2026, supported by new products entering the national medical insurance [7]. - Licensing income is expected to reach RMB 3.39 billion in 2025, with further contributions from collaborations, including a projected USD 250 million from GSK [7]. Valuation Metrics - The company's current valuation is considered reasonable, with target prices reflecting a potential upside of 5% in the Hong Kong market and 14% in the A-share market [2][7]. - The DCF valuation model indicates a per-share value of RMB 63.18 or HKD 69.50 [8].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company's performance in the renewable energy sector is recovering, driven by an increase in installed capacity and improved wind conditions, with a projected 6.78% year-on-year growth in wind power generation in 2025 [2][6]. - The natural gas business is under pressure due to a significant decline in gas sales volume, resulting in a 25.01% year-on-year decrease in net profit for this segment [2][6]. - Despite challenges in the natural gas sector, the overall net profit for the company is expected to reach 18.26 billion yuan in 2025, reflecting a year-on-year increase of 9.21% [2][6]. Summary by Sections Revenue and Profitability - In 2025, the company achieved operating revenue of 19.831 billion yuan, a decrease of 7.21% year-on-year, while the net profit attributable to shareholders was 18.26 billion yuan, an increase of 9.21% year-on-year [6]. Renewable Energy Performance - The company added 1.2705 million kilowatts of wind power capacity in 2025, bringing the total to 7.778 million kilowatts, a year-on-year increase of 18.07%. Wind power generation reached 14.85 billion kilowatt-hours, up 6.78% year-on-year [2][9]. - The photovoltaic segment also saw growth, with installed capacity reaching 424,800 kilowatts, a 15.06% increase, and generation increasing by 68.14% year-on-year to 360 million kilowatt-hours [9]. Natural Gas Business - The total gas sales volume decreased by 10.71% year-on-year to 5.255 billion cubic meters, with net profit from this segment falling to 358 million yuan, down 25.01% year-on-year [2][9]. Strategic Adjustments - The company is shifting its focus away from photovoltaic investments and plans to gradually divest its existing photovoltaic projects, while enhancing its wind power capacity with 1.2981 million kilowatts under construction [9]. Dividend Policy - The company plans to distribute a cash dividend of 0.2 yuan per share for 2025, maintaining a dividend payout ratio of 49.42%, which corresponds to a dividend yield of 5.11% based on the stock price as of March 25, 2026 [9].

Investment Rating - The investment rating for TCL Electronics is "Buy" (maintained) [3] Core Views - The report highlights that TCL Electronics is entering a new phase of global market share enhancement driven by large-size new products [1] - The company reported a revenue increase of 15.4% to HKD 114.58 billion for 2025, with adjusted net profit rising by 56.5% to HKD 2.51 billion [8] - The report anticipates that the company will continue its upward trend in 2025 and 2026, supported by product structural optimization and channel expansion in North America and Europe [8] Financial Performance Summary - Revenue projections for TCL Electronics are as follows: - 2024A: HKD 99.32 billion - 2025A: HKD 114.58 billion - 2026E: HKD 126.96 billion - 2027E: HKD 143.28 billion - 2028E: HKD 158.13 billion - The revenue growth rates are projected at 25.75% for 2024, 15.36% for 2025, and 10.80% for 2026 [7] - The adjusted net profit forecasts are: - 2026E: HKD 2.96 billion - 2027E: HKD 3.43 billion - 2028E: HKD 4.04 billion - The report indicates a PE ratio of 9.38 for 2026 and 8.10 for 2027, suggesting a favorable valuation [7][8] Segment Performance - Domestic TV revenue decreased by 9.7% to HKD 17.2 billion, while overseas TV revenue increased by 15.7% to HKD 47.5 billion, with North America and Europe showing strong growth [8] - Internet revenue grew by 18.3% to HKD 3.11 billion, driven by partnerships with major platforms like Google and Netflix [8] - The solar business saw a significant revenue increase of 63.6% to HKD 21.06 billion, with over 340 signed projects and approximately 36,000 household installations [8]

Investment Rating - The report maintains a "Buy" rating for China Biologic Products (1177 HK) with a target price of HKD 7.70, indicating a potential upside of 30.8% from the current closing price of HKD 5.89 [2][6][9]. Core Insights - The company is expected to achieve strong profit growth in 2025, driven by its leading commercialization capabilities in mainland China, particularly in oncology and biosimilars, which are projected to drive double-digit revenue growth [2][5]. - The global expansion strategy is advancing rapidly through various means such as business development, acquisitions, and strategic partnerships, indicating a multi-faceted approach to growth [2][5]. - The company is evolving into a local multinational corporation (MNC) with nearly 20 new products or indications expected to be approved by 2026-2028, including innovative therapies with first-in-class potential [5][10]. Financial Forecasts - Revenue projections for 2026 are set at RMB 35,989 million, a decrease of 3% from previous estimates, with adjusted net profit expected to be RMB 4,208 million, reflecting an 11% reduction [4][10]. - The gross profit margin is forecasted to be 83.0% for 2026, slightly down from 83.5% in prior estimates [4][10]. - The company anticipates maintaining double-digit growth in product sales from 2026 to 2027, supported by new product launches and market expansions [5][10]. Stock Performance - The stock has shown a 52-week high of HKD 9.01 and a low of HKD 3.34, with a current market capitalization of approximately HKD 105.35 billion [4][10]. - Year-to-date performance has seen a decline of 4.69% [4][10]. Market Position - The report highlights that the company is positioned as a comprehensive pharmaceutical innovation platform, transitioning from a local drug developer to a global player in the pharmaceutical industry [5][10].

Investment Rating - The report maintains a "Buy" rating for AIA Group (1299 HK) with an updated target price of HKD 101, indicating a potential upside of 17.9% [1]. Core Insights - AIA Group's 2025 performance is expected to show resilience despite short-term fluctuations due to factors like USD depreciation, driven by growth in new markets and businesses, with operational profit projected to reach USD 7.895 billion in 2026 [1]. - The company emphasizes a long-term strategy focused on "value growth over scale expansion," reaffirmed by management during the earnings release [6]. - The report updates the earnings forecasts for 2026-2028, predicting premium income growth rates of 10%, 9%, and 7% respectively, with strong contributions from the Hong Kong and mainland China markets [6]. Financial Performance - For 2025, AIA Group reported an operational profit (OPAT) of USD 7.14 billion, a year-on-year increase of approximately 7%, and a net profit of USD 6.23 billion, which, while lower than 2024, exceeded market expectations [6]. - The insurance services segment achieved a performance of USD 6.91 billion, reflecting a year-on-year growth of 19.8%, while investment returns surged by 50.6% to USD 17.98 billion [6]. - The report highlights a solid customer base and strong cash flow generation capabilities, with a projected basic free earnings per share (UFSG) growth of around 11% for 2025 [6]. Earnings Forecast Changes - The updated earnings forecasts for 2026 show a slight increase in net profit from USD 6.584 billion to USD 6.714 billion, representing a 1.97% change, while operational profit is revised up by 4.28% to USD 7.895 billion [5]. - The new business value is also adjusted upward, with a forecast of USD 6.105 billion for 2026, reflecting a 1.11% increase [5]. - The report anticipates a robust growth trajectory for new business value margins, projected to increase by 10%, 8%, and 7% over the next three years [6].

Investment Rating - The report upgrades the investment rating of the company to "Buy" from "Neutral" [2][6] Core Insights - The company's performance exceeded expectations, with a significant increase in overseas revenue contribution, leading to an upgrade in the investment rating [2][6] - In Q4 2025, the company reported revenues of 3.1 billion RMB and a net profit of 343 million RMB, which was better than market expectations despite a year-on-year revenue decline of 24% [2][6] - The gross margin improved significantly by 7.5 percentage points to 24.3% due to a decrease in raw material costs and high glass prices from Q3 2025 [2][6] Financial Overview - Revenue projections for the company show a decline from 18.7 billion RMB in 2024 to 15.1 billion RMB in 2026E, with a projected growth of 9.0% in 2027 and 10.8% in 2028 [5][13] - The net profit is expected to stabilize around 1.0 billion RMB in 2026E, with a gradual increase to 1.7 billion RMB by 2028 [5][13] - The company’s gross margin is projected to fluctuate, with a slight decrease to 14.8% in 2026E, followed by an increase to 17.9% in 2028E [8][13] Market Position and Strategy - The company has increased its advanced production capacity, which is expected to enhance its cost advantage in the long term despite short-term competitive pressures [6][8] - The overseas revenue contribution rose significantly, accounting for 34.7% of total revenue, which positively impacted the gross margin [6][8] - The company is strategically investing in advanced production capabilities to clear outdated capacities, which is expected to strengthen its market position [6][8]